-
Something wrong with this record ?
Olomoucine II, but not purvalanol A, is transported by breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1)
J. Hofman, R. Kučera, D. Cihalova, J. Klimes, M. Ceckova, F. Staud,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Directory of Open Access Journals
from 2006
Free Medical Journals
from 2006
Public Library of Science (PLoS)
from 2006
PubMed Central
from 2006
Europe PubMed Central
from 2006
ProQuest Central
from 2006-12-01
Open Access Digital Library
from 2006-01-01
Open Access Digital Library
from 2006-10-01
Open Access Digital Library
from 2006-01-01
Medline Complete (EBSCOhost)
from 2008-01-01
Nursing & Allied Health Database (ProQuest)
from 2006-12-01
Health & Medicine (ProQuest)
from 2006-12-01
Public Health Database (ProQuest)
from 2006-12-01
ROAD: Directory of Open Access Scholarly Resources
from 2006
- MeSH
- ATP-Binding Cassette Transporters metabolism MeSH
- Biological Transport MeSH
- Cell Line MeSH
- Drug Resistance, Neoplasm drug effects MeSH
- Neoplasm Proteins metabolism MeSH
- ATP Binding Cassette Transporter, Subfamily B, Member 1 metabolism MeSH
- Dogs MeSH
- Purines pharmacokinetics MeSH
- Animals MeSH
- Check Tag
- Dogs MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Purine cyclin-dependent kinase inhibitors have been recognized as promising candidates for the treatment of various cancers; nevertheless, data regarding interaction of these substances with drug efflux transporters is still lacking. Recently, we have demonstrated inhibition of breast cancer resistance protein (ABCG2) by olomoucine II and purvalanol A and shown that these compounds are able to synergistically potentiate the antiproliferative effect of mitoxantrone, an ABCG2 substrate. In this follow up study, we investigated whether olomoucine II and purvalanol A are transported by ABCG2 and ABCB1 (P-glycoprotein). Using monolayers of MDCKII cells stably expressing human ABCB1 or ABCG2, we demonstrated that olomoucine II, but not purvalanol A, is a dual substrate of both ABCG2 and ABCB1. We, therefore, assume that pharmacokinetics of olomoucine II will be affected by both ABCB1 and ABCG2 transport proteins, which might potentially result in limited accumulation of the compound in tumor tissues or lead to drug-drug interactions. Pharmacokinetic behavior of purvalanol A, on the other hand, does not seem to be affected by either ABCG2 or ABCB1, theoretically favoring this drug in the potential treatment of efflux transporter-based multidrug resistant tumors. In addition, we observed intensive sulfatation of olomoucine II in MDCKII cell lines with subsequent active efflux of the metabolite out of the cells. Therefore, care should be taken when performing pharmacokinetic studies in MDCKII cells, especially if radiolabeled substrates are used; the generated sulfated conjugate may largely contaminate pharmacokinetic analysis and result in misleading interpretation. With regard to chemical structures of olomoucine II and purvalanol A, our data emphasize that even drugs with remarkable structure similarity may show different pharmacokinetic behavior such as interactions with ABC transporters or biotransformation enzymes.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14063905
- 003
- CZ-PrNML
- 005
- 20140707113453.0
- 007
- ta
- 008
- 140704s2013 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1371/journal.pone.0075520 $2 doi
- 035 __
- $a (PubMed)24116053
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Hofman, Jakub $u Department of Pharmacology and Toxicology, Charles University in Prague, Faculty of Pharmacy, Hradec Kralove, Czech Republic.
- 245 10
- $a Olomoucine II, but not purvalanol A, is transported by breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1) / $c J. Hofman, R. Kučera, D. Cihalova, J. Klimes, M. Ceckova, F. Staud,
- 520 9_
- $a Purine cyclin-dependent kinase inhibitors have been recognized as promising candidates for the treatment of various cancers; nevertheless, data regarding interaction of these substances with drug efflux transporters is still lacking. Recently, we have demonstrated inhibition of breast cancer resistance protein (ABCG2) by olomoucine II and purvalanol A and shown that these compounds are able to synergistically potentiate the antiproliferative effect of mitoxantrone, an ABCG2 substrate. In this follow up study, we investigated whether olomoucine II and purvalanol A are transported by ABCG2 and ABCB1 (P-glycoprotein). Using monolayers of MDCKII cells stably expressing human ABCB1 or ABCG2, we demonstrated that olomoucine II, but not purvalanol A, is a dual substrate of both ABCG2 and ABCB1. We, therefore, assume that pharmacokinetics of olomoucine II will be affected by both ABCB1 and ABCG2 transport proteins, which might potentially result in limited accumulation of the compound in tumor tissues or lead to drug-drug interactions. Pharmacokinetic behavior of purvalanol A, on the other hand, does not seem to be affected by either ABCG2 or ABCB1, theoretically favoring this drug in the potential treatment of efflux transporter-based multidrug resistant tumors. In addition, we observed intensive sulfatation of olomoucine II in MDCKII cell lines with subsequent active efflux of the metabolite out of the cells. Therefore, care should be taken when performing pharmacokinetic studies in MDCKII cells, especially if radiolabeled substrates are used; the generated sulfated conjugate may largely contaminate pharmacokinetic analysis and result in misleading interpretation. With regard to chemical structures of olomoucine II and purvalanol A, our data emphasize that even drugs with remarkable structure similarity may show different pharmacokinetic behavior such as interactions with ABC transporters or biotransformation enzymes.
- 650 _2
- $a ABC transportéry $x metabolismus $7 D018528
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a biologický transport $7 D001692
- 650 _2
- $a buněčné linie $7 D002460
- 650 _2
- $a psi $7 D004285
- 650 _2
- $a chemorezistence $x účinky léků $7 D019008
- 650 _2
- $a nádorové proteiny $x metabolismus $7 D009363
- 650 _2
- $a P-glykoprotein $x metabolismus $7 D020168
- 650 _2
- $a puriny $x farmakokinetika $7 D011687
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Kučera, Radim
- 700 1_
- $a Cihalova, Daniela
- 700 1_
- $a Klimes, Jiri
- 700 1_
- $a Ceckova, Martina
- 700 1_
- $a Staud, Frantisek
- 773 0_
- $w MED00180950 $t PloS one $x 1932-6203 $g Roč. 8, č. 10 (2013), s. e75520
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/24116053 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20140704 $b ABA008
- 991 __
- $a 20140707113741 $b ABA008
- 999 __
- $a ok $b bmc $g 1031389 $s 862637
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 8 $c 10 $d e75520 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
- LZP __
- $a Pubmed-20140704